Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1
Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume
Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume
The company will provide the necessary response to USFDA within stipulated 15 days
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
The company received seven observations in the Form-483
UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Subscribe To Our Newsletter & Stay Updated